In today’s newsletter: In today’s newsletter: Scotland’s new Hate Crime and Public Order (Scotland) Act was supposed to protect its most vulnerable communities. Instead, it’s served only to create even bigger divides
Parkinson s UK Implements CDD Vault to Manage Its Pioneering Drug Discovery Data
USA - English
Share this article
Share this article
LONDON and SAN FRANCISCO, July 19, 2021 /PRNewswire/ Parkinson s UK, the largest charitable funder of Parkinson s research in Europe, has announced today that it is using Collaborative Drug Discovery s CDD Vault informatics system to manage project data from the Parkinson s Virtual Biotech, its pioneering drug discovery arm.
The Parkinson s Virtual Biotech, which launched in 2017, is a program that is plugging the funding gap in drug development to fast-track the projects with the greatest scientific potential to transform the lives of people with Parkinson s. As part of the collaboration, CDD Vault will help the charity keep its research data safe and secure. It will also enable scientists to analyze data and design the next set of biological molecules.
Apr 26 2021 Read 13 Times
Researchers at the University of Sheffield have been awarded £1.2 million from Parkinson’s UK to continue with development of a drug that protects dopamine-producing brain cells in efforts to halt the degenerative disease.
Dopamine is a chemical which allows messages to be sent to the parts of the brain that help to coordinate movement. To do this effectively, the dopamine-producing brain cells need to be constantly active and they rely on mitochondria to function properly.
Scientists from the University’s Institute of Translational Neuroscience (SITraN) led by Dr Heather Mortiboys, have been working with experts from Parkinson’s UK to develop molecules that can boost the function of the brain’s energy-producing mitochondria.
Parkinson’s UK, University of Sheffield to develop new Parkinson’s drug
Parkinson s UK, the largest charitable funder of Parkinson s research in Europe, is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield.
The project aims to refine a molecule that could be developed into a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson s.
The funding boost comes via the charity s Parkinson s Virtual Biotech initiative, which is plugging the funding gap in drug development and fast-tracking the development of new treatments for people with Parkinson s.
Scientists at the University of Sheffield s Institute of Translational Neuroscience (SITraN) and Parkinson s UK have been developing molecules that can boost the function of the brain s energy-producing mitochondria, to halt Parkinson s - something no treatment can currently do.